Medical Devices

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.

With TGA approval, Optellum's AI platform arrives to help tackle Australia's low lung cancer survival rates by enabling earlier, more accurate detection.

With $13M in new funding, BrainCheck is expanding its AI platform to help doctors detect dementia earlier and manage cognitive care at scale.

GEMMABio has dosed the first infant in a trial for its next-gen SMA1 gene therapy, a new approach designed to improve safety and global access.

A new $3M endowed professorship at UMSOM, funded by state and private partners, aims to accelerate medical innovation by bridging engineering and medicine.

Beyond software, an Upstate NY incubator is tackling global challenges in health, climate, and ag-tech, turning physical ideas into world-changing products.

With the hire of Greg Crescenzi, the famed academic repository signals a major strategic expansion to bridge the gap between scientific sharing and drug development.

Calyxo's CVAC System shows a dramatic reduction in repeat procedures and costs, but recent safety warnings add complexity to its widespread adoption.

Heron Therapeutics posts record growth fueled by ZYNRELEF and APONVIE, issuing strong 2026 guidance and signaling a successful pivot to profitability.

Sensus Healthcare's new Sensus Link software aims to upgrade existing skin cancer treatment systems, signaling a major strategic shift to the cloud.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

PROCEPT BioRobotics reports record Aquablation procedures but lowers 2026 revenue guidance, signaling a strategic shift for long-term profitability.